Condition: Healthy Adult Participants · Sponsor: NeuHyll AUS Pty Ltd
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of NHL907 when administered as multiple oral doses in healthy adult participants.
This description comes directly from the study's public registry record.
James Connell, MD · +61 (0)8 7088 7900 · james.connell@cmax.com.au
Always discuss trial participation with your own doctor first.
| CMAX Clinical Research Pty Ltd | Adelaide, South Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07580924